-
Mashup Score: 4APCCC 2021: Best Use of Lutetium-PSMA and Where To Put It in Sequencing Therapies Including Treatment Monitoring - 3 year(s) ago
APCCC 2021 PSMA in diagnostics and therapy, Lutetium-PSMA and where to place it when sequencing therapies, Lutetium-PSMA treatment monitoring prostate cancer.
Source: www.urotoday.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 16APCCC 2021: What Is the Evidence for “Triplet Therapy”? - 3 year(s) ago
APCCC 2021 newly diagnosed metastatic hormone-sensitive prostate cancer, ADT + docetaxel + primary additional systemic therapy, TITAN trial, ARCHES trial, ENZAMET trial.
Source: www.urotoday.comCategories: Latest Headlines, Oncologists1Tweet-
Evidence of 'triplet therapy' (ADT + doce + additional systemic Rx) in mHSPC from @Prof_IanD #APCCC21 Best evidence in ENZAMET (ADT + doce + enza): no OS benefit yet (50% of events), but strong PFS signal for triplet @urotoday @APCCC_Lugano @ANZUPtrials https://t.co/ZQflxJsF1S https://t.co/tBBfZMlgSD
-
-
Mashup Score: 5APCCC 2021: Contagious Enthusiasm in PSMA-Driven Therapeutics - 3 year(s) ago
APCCC 2021 VISION, PSMA in diagnostics and therapy, PSMA-driven therapeutics, VISION study outcomes, 177Lu-PSMA-617 targeted radioligand therapy improving overall survival (OS), radiographic PFS, and quality of life by a significant margin in advance metastatic castration resistant prostate cancer (mCRPC)
Source: www.urotoday.comCategories: Latest Headlines, Oncologists1Tweet-
Contagious Enthusiasm in PSMA-Driven Therapeutics by @EfstathiouEleni #APCCC21 📍177Lu-PSMA trials earlier in the disease Stay tuned for upcoming: 📍PSMA-targeted bispecific T-cell engager (BiTE) immunother 📍PSMA-targeted CAR-T @urotoday @APCCC_Lugano https://t.co/iBlajuILnZ https://t.co/FfGqWuBLOw
-
-
Mashup Score: 5
APCCC 2021 the role of prostate specific membrane antigen (PSMA) imaging in prostate cancer diagnostics and therapy, potential pitfalls of different PSMA-based radiotracers in prostate cancer care
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
PSMA – based imaging: Navigating the pitfalls of the different tracers. Presentation by @stefanofanti4. #APCCC21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/Y4UsFtxA5b @APCCC_Lugano https://t.co/DElGYlNvm3
-
-
Mashup Score: 11
APCCC 2021 Misha Beltran, new molecular data available with PSMA PET scans, molecular markers to inform treatment decisions in mHSPC, clinical need for biomarkers to optimally select treatment for men with mHSPC.
Source: www.urotoday.comCategories: Latest Headlines, Oncologists2Tweet-
#APCCC21 Update: @mishabeltran's summary of how molecular markers can inform mHSPC tx decisions was a tour de force! And nice to see impt work from pals @anis_a_hamid @aloktewar highlighted. Missed it? Check out my @APCCC_Lugano summary for @urotoday... https://t.co/0OaTBYDZwT https://t.co/Je4khthRrA
-
-
Mashup Score: 3APCCC 2021: Management of Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Review of Panel Responses and Discussion - 3 year(s) ago
APCCC 2021 the management of metastatic hormone sensitive prostate cancer (mHSPC)
Source: www.urotoday.comCategories: Latest Headlines, Oncologists2Tweet-
#APCCC21 Update: Lots of valuable insights from panel members' responses to questions on management of mHSPC. Less consensus than you might imagine, which led to a great discussion... Missed it? Check out my @APCCC_Lugano summary for @urotoday... https://t.co/SCvij1B8y6 https://t.co/QWad0Rslb2
-
-
Mashup Score: 19
APCCC 2021 role of prostate specific membrane antigen (PSMA) imaging in prostate cancer diagnostics and therapy, role of PSMA diagnosis and theranostics, PSMA-PET/CT, radical prostatectomy for high-risk localized disease, role of Lu-PSMA therapy.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
A summary of Panel Responses Regarding PSMA in Diagnostics and Therapy @AlbertoBossial @declangmurphy @Silke_Gillessen. #APCCC21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/JQxHDbvbZG @APCCC_Lugano https://t.co/3lMUOQP64p
-
-
Mashup Score: 4APCCC 2021: Do We Need the Second PET (FDG) for Patient Selection? (Including SUV for Selection of PSMA Therapy) - 3 year(s) ago
APCCC 2021 role of prostate specific membrane antigen (PSMA) imaging in prostate cancer diagnostics and therapy, FDG-PET/CT, lutetium-PSMA (Lu-PSMA) therapy, VISION trial, PSMA-negative, PSMA-PET SUVmax.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Do we need the second PET (FDG) for patient selection? (including SUV for selection of PSMA therapy). Presentation by @DrMHofman @PeterMacCC. #APCCC21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/COPSJt6GNY @APCCC_Lugano https://t.co/w4xiK7KCys
-
-
Mashup Score: 7
APCCC 2021 molecular characterization of both tissue and blood, with a focus on implications for treatment with PARP inhibitors and beyond.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Summary of panel responses regarding tumor molecular testing. Presentation by Matthew R. Smith, MD, Ph.D., and @MGHMedicine and Nicolas Mottet, MD, PhD @ChuSaintEtienne. #APCCC21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/lGEpv8ruZw @APCCC_Lugano https://t.co/Ob5KqxMC0e
-
-
Mashup Score: 8
COVID-19 pandemic, androgen deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer, approval of enzalutamide, mRNA profiling, GETUG-15 data, STAMPEDE trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Are there still patients where treatment with ADT alone is appropriate? Presentation by Professor Robert Jones @UofGlasgow. #APCCC21 written coverage by @WallisCJD @UofT on UroToday > https://t.co/35bGC8l7SP @APCCC_Lugano https://t.co/upVovGuwiZ
-
Great #APCCC21 talk from @charlesryanmd putting 177-Lu-PSMA RLT into context across the #ProstateCancer continuum After VISION and TheraP, earlier trials in the disease space: PSMAfore PSMAddition LuTectomy @urotoday @APCCC_Lugano @PCFnews @PCF_Science https://t.co/2TRBstbjEZ https://t.co/q2TwZXmn08